Tissue Engineering Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 12.80 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
| Market Concentration | Low |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Tissue Engineering Market Analysis
The tissue engineering market is expected to register a CAGR of nearly 12.8% during the forecast period (2022-2027).
There have been effects of the COVID-19 pandemic on different surgical techniques. As a result of the lockdown restrictions, individuals with various lifestyle-related and chronic conditions had a delay in diagnosis and treatments, which affected the market under study. As per a study published in March 2021 entitled "Combating COVID-19 with tissue engineering: a review" after COVID-19, the lungs may sustain significant damage, particularly as a result of cytokine overexpression. Mesenchymal stem cells (MSCs) can repair injured lung tissue, stabilize endothelial fluid leaks, and decrease the alveolar-capillary barrier function, which helps to prevent the formation of interstitial lung edema. Since COVID-19 causes significant organ damage, tissue engineering plays a significant role in repairing lung tissue that has been destroyed. However, the market under study is anticipated to return to its full potential over time due to continued immunizations and a decline in COVID-19 cases.
Globally, there has been an increasing incidence of chronic diseases such as orthopedic, cardiovascular, and neurology disorders, which are leading to disability and negatively impacting people's physical and mental well-being. According to the study titled 'Sexuality and relationship experiences of women with spinal cord injury: reflections from an Indian context' published in the Sexual and Reproductive Health Matter in May 2022, around 250,000-500,000 persons worldwide suffer a spinal cord injury (SCI) each year. The most frequent causes of SCI include falls, violent acts, and traffic injuries. Men sustain these injuries at a rate of about 80%. Thus, chronic diseases are the leading causes of death and disability worldwide, which is expected to drive the market growth over the forecast period.
The rising chronic diseases, road accidents, and trauma injuries are found to be contributing to the growth in the development of tissue engineering solutions. There is an increasing number of people in need of bone implants that are on the rise owing to the increasing cases of chronic diseases, trauma cases, and growing average life span. According to the World Health Organization (WHO) Report 2021, each year 20-50 million people suffer from non-fatal injuries, with many incurring a disability as a result of their injury. 93% of the world's fatalities on the roads occur in low and middle-income countries, even though these countries have approximately 60% of the world's vehicles. Even within high-income countries, individuals from lower socioeconomic backgrounds are more likely to be involved in road traffic crashes. Thus, increasing road traffic-related crashes result in injuries, which is expected to boost the market growth.
Though the procedures are quite promising for the treatment of various conditions involving tissue damage; the high cost associated with these procedures is one of the major factors limiting their adoption among patients.
Tissue Engineering Market Trends
This section covers the major market trends shaping the Tissue Engineering Market according to our research experts:
Orthopedic Segment is Expected to Show the Fastest Growth During the Forecast Period
Bone tissue engineering is concerned with creating implantable bone substitutes for critical skeletal defects that cannot heal on their own. These defects are common clinical scenarios in orthopedics surgeries for the treatment of bone loss due to trauma, infection, and tumor resection. Moreover, tissue engineering has become a vital option for orthopedic surgeons in the treatment of a variety of musculoskeletal lesions, ranging from osteochondral defects in the glenohumeral joint to meniscal deficiency in young athletes. According to the study titled 'The global prevalence of rheumatoid arthritis: a meta-analysis based on a systematic review' published in the Rheumatology International in May 2021, between 1980 and 2019, there were 460 cases of rheumatoid arthritis per 100,000 people worldwide. Thus, the growing prevalence of orthopedic diseases supports the segment growth.
Segment expansion is anticipated to be aided by the fact that market participants often launch new products and employ a range of growth strategies in their specific segments. For instance, in March 2021, Sparta Biopharma Inc., a privately-held company, launched BioEnthesisTM, the allograft that has both mineralized and demineralized layers, which provide the requisite properties for healing and repair within the rotator cuff. Similarly, in November 2020, AlloSource presented positive results for a 12-month follow-up in its five-year study titled " A Prospective, Multi-Center Study Evaluating ProChondrix CR for the Repair of Focal Articular Cartilage Defects in the Knee" looking at the long-term outcomes of ProChondrix CR, a cryopreserved osteochondral allograft in the knee.
Thus, the rising burden of orthopedic disorders, along with frequent product launches in the respective segment, is expected to drive the segment growth significantly during the forecast period.
North America to Dominate the Market During the Forecast Period
The United States market growth is majorly driven by factors, such as the increasing incidence of chronic diseases, road accidents, and trauma Injuries, technological advancements in 3D tissue engineering, and the presence of key market players. According to the Centers for Disease Control and Prevention (CDC) updated in October 2021, compared to the 58.5 million individuals with arthritis in 2013-2015, it is predicted that by 2040, 78.4 million adults aged 18 and older (or 25.9% of the anticipated total adult population) are likely to be diagnosed with the condition. Furthermore, according to America's Health Rankings Senior Report published in 2021, the number of older adults living in the United States is significant and growing; by 2050, it is anticipated that there will be 85.7 million adults in the country who are 65 or older. Such a high prevalence of this disease along with the aging population is likely to increase the adoption of therapies for this, driving the market growth and the aging population which supports the market expansion.
The growing product launches by the market players support the market growth For instance, in September 2020, Histogen Inc., a clinical-stage therapeutics company, was awarded a USD 2 million grant by the Peer Reviewed Orthopedic Research Program (PRORP) of the United States Department of Defense (DoD) to help fund a Phase 1/2 clinical trial of HST-003 for regeneration of cartilage in the knee. Furthermore, in July 2020, Amnio Technology also received approval from the United States Food and Drug Administration to proceed phase II clinical trial for Pallingen Flow, an amniotic tissue allograft. Additionally, in January 2021, Direct Biologics LLC launched AmnioWrap placental-based sheet allografts for clinical use. AmnioWrap is a unique, tri-layer graft intended for applications in acute and chronic wounds.
As a result, the region is expected to experience exponential growth due to the presence of market-propelling factors.
Tissue Engineering Industry Overview
There has been a presence of a considerable number of companies that are significantly contributing to market growth. New product breakthroughs, mergers, and acquisitions are just a few of the tactics these businesses have used to increase their market position. Also, there are many companies that are upgrading their product portfolios in order to meet the current demand. Some of the key players are B. Braun Melsungen AG, Zimmer Biomet, Integra Lifescience, abbvie and among others.
Tissue Engineering Market Leaders
-
Zimmer Biomet
-
B. Braun Melsungen AG
-
Integra Lifesciences
-
AbbVie (Allergan)
-
Becton, Dickinson and Company (C.R. Bard)
*Disclaimer: Major Players sorted in no particular order
Tissue Engineering Market News
- In May 2022, Rousselot, Darling Ingredients' health brand, has launched Quali-Pure HGP 2000, a new endotoxin-controlled, pharmaceutical-grade gelatin specifically designed for vaccines and wound healing applications.
- In February 2022, Orthofix Medical has launched a synthetic bioactive bone graft solution, Opus BA, for cervical and lumbar spine fusion procedures.
Tissue Engineering Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increase Incidences of Chronic Diseases, Road Accidents, and Trauma Injuries
4.2.2 Technological Advancements in 3D Tissue Engineering
4.2.3 Increase in Funding and Research for Tissue Regeneration
4.3 Market Restraints
4.3.1 High Cost of Treatments Related to Tissue Engineering
4.3.2 Lack of Awareness Regarding Tissue Engineering
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD Million)
5.1 By Material
5.1.1 Synthetic Materials
5.1.2 Biologically Derived Materials
5.1.3 Others
5.2 By Application
5.2.1 Orthopedics
5.2.2 Musculoskeletal & Spine
5.2.3 Neurology
5.2.4 Cardiology & Vascular
5.2.5 Skin & Integumentary
5.2.6 Others
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 AbbVie Inc. (Allergan)
6.1.2 Integra Lifesciences
6.1.3 Becton, Dickinson and Company (C. R. Bard)
6.1.4 Zimmer Biomet
6.1.5 Organogenesis
6.1.6 Smith and Nephew (Osiris Therapeutics)
6.1.7 Biotime Inc.
6.1.8 B. Braun Melsungen AG
6.1.9 Bio Tissue Technologies
6.1.10 Acell Inc.
6.1.11 Athersys Inc.
6.1.12 Tissue Regenix Group plc
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Tissue Engineering Industry Segmentation
As per the scope of the report, tissue engineering is the use of a combination of cells, engineering, and other materials methods, and suitable biochemical and physicochemical factors to improve or replace the biological tissues. It is gaining traction in various areas such as wound care, burn treatment, orthopedics, neurology, urological products, and others. It also plays an important role in the management of pediatric patients. The Tissue Engineering Market is segmented by Material (Synthetic Materials, Biologically Derived Materials and Others), Application (Orthopedics, Musculoskeletal & Spine, Neurology, Cardiology & Vascular, Skin & Integumentary, Others) and Geography (North America, Europe, Asia Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.
| By Material | |
| Synthetic Materials | |
| Biologically Derived Materials | |
| Others |
| By Application | |
| Orthopedics | |
| Musculoskeletal & Spine | |
| Neurology | |
| Cardiology & Vascular | |
| Skin & Integumentary | |
| Others |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Tissue Engineering Market Research FAQs
What is the current Global Tissue Engineering Market size?
The Global Tissue Engineering Market is projected to register a CAGR of 12.80% during the forecast period (2024-2029)
Who are the key players in Global Tissue Engineering Market?
Zimmer Biomet, B. Braun Melsungen AG, Integra Lifesciences, AbbVie (Allergan) and Becton, Dickinson and Company (C.R. Bard) are the major companies operating in the Global Tissue Engineering Market.
Which is the fastest growing region in Global Tissue Engineering Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Tissue Engineering Market?
In 2024, the North America accounts for the largest market share in Global Tissue Engineering Market.
What years does this Global Tissue Engineering Market cover?
The report covers the Global Tissue Engineering Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Tissue Engineering Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Tissue Engineering Industry Report
Statistics for the 2024 Tissue Engineering market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Tissue Engineering analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
